Real World & Health Data Sets
Richer real world data insights can drive smarter decisions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare Solutions
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORECase Study
Safety Risks of Therapy Used to Treat COVID-19
Observational Study
Aug 18, 2020
Healthcare providers have an urgent need to understand the safety and efficacy of the various therapies being used to treat COVID-19. In the early days of the pandemic, the FDA had granted emergency authorization to use hydroxychloroquine (HCQ), and many providers were using it alone and/or in combination with azithromycin (AZM).
Both drugs, however, have the potential to cause life-threatening arrhythmias. There was, therefore, a critical need to know what risk the combination posed in short-term use to treat COVID-19 patients. To address this need, IQVIA experts conducted a global observational study utilizing real world data to provide immediate answers for treatment decisions.
Download our case study to learn:
- Details on the round-the-clock virtual meeting, including the design and execution of multiple simultaneous studies
- Results of the eight observational studies, including examination of the safety of using HCQ alone and in combination with AZM in rheumatoid arthritis patients
- Why the IQVIA study-a-thon has become a catalyst for the creation of an ongoing COVID-19 study group
Related solutions
Real World Evidence
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.